Pages that link to "Q40187920"
Jump to navigation
Jump to search
The following pages link to Clinical and in vitro studies of imatinib in advanced carcinoid tumors (Q40187920):
Displaying 39 items.
- Medical treatment for gastro-entero-pancreatic neuroendocrine tumours (Q26751659) (← links)
- From targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumors (Q26822011) (← links)
- Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors (Q26823873) (← links)
- Target therapy in metastatic pheochromocytoma: current perspectives and controversies (Q28087343) (← links)
- Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors (Q28290833) (← links)
- Neuroendocrine tumors of the gastro-entero-pancreatic system (Q28294432) (← links)
- Well-differentiated neuroendocrine tumors: a review covering basic principles to loco-regional and targeted therapies (Q33840177) (← links)
- Successful imatinib therapy for neuroendocrine carcinoma with activating Kit mutation: a case study (Q33957571) (← links)
- Gastric neuroendocrine tumours (Q34306680) (← links)
- Targeted therapy in advanced well-differentiated neuroendocrine tumors (Q35584497) (← links)
- Pancreatic endocrine tumours: mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines and rare primaries (Q35747269) (← links)
- A new era for the systemic therapy of neuroendocrine tumors (Q35863865) (← links)
- Emerging approaches in the management of patients with neuroendocrine liver metastasis: role of liver-directed and systemic therapies (Q36512778) (← links)
- Emerging therapies for the treatment of patients with advanced neuroendocrine tumors (Q36866607) (← links)
- Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours (Q36892294) (← links)
- Medical treatment of gastrinomas (Q36994231) (← links)
- Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study (Q37121673) (← links)
- Pancreatic neuroendocrine tumors: approach to treatment with focus on sunitinib (Q37130616) (← links)
- Gastric carcinoid tumor in a patient with a past history of gastrointestinal stromal tumor of the stomach (Q37413303) (← links)
- Accomplishments in 2008 in the management of gastrointestinal neuroendocrine tumors. (Q37468838) (← links)
- Molecular targeted therapies in the treatment of gastroenteropancreatic neuroendocrine tumors (Q37629704) (← links)
- A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors (Q37640526) (← links)
- Gastroenteropancreatic neuroendocrine tumors: recommendations of Turkish multidisciplinary neuroendocrine tumor study group on diagnosis, treatment and follow-up (Q37675588) (← links)
- The molecular pathogenesis and management of bronchial carcinoids (Q37833109) (← links)
- Changing paradigms in the treatment of malignant pheochromocytoma (Q37859612) (← links)
- Novel medical therapies of recurrent and metastatic gastroenteropancreatic neuroendocrine tumors. (Q37936908) (← links)
- Emerging therapeutic options for advanced enteropancreatic neuroendocrine tumors. (Q37980202) (← links)
- The role of cell lines in the study of neuroendocrine tumors (Q38005913) (← links)
- Management of advanced and/or metastatic carcinoid tumors: historical perspectives and emerging therapies (Q38112804) (← links)
- Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors (Q39773838) (← links)
- Role of radiopharmaceuticals in the diagnosis and treatment of neuroendocrine tumours (Q39944711) (← links)
- Characterization of the functional and growth properties of cell lines established from ileal and rectal carcinoid tumors (Q40017021) (← links)
- Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives (Q43097453) (← links)
- Five patients with malignant endocrine tumors treated with imatinib mesylate (Glivec). (Q43184601) (← links)
- High KIT and PDGFRA are associated with shorter patients survival in gastroenteropancreatic neuroendocrine tumors, but mutations are a rare event. (Q54334587) (← links)
- Imatinib attenuates hypoxia-induced pulmonary arterial hypertension pathology via reduction in 5-hydroxytryptamine through inhibition of tryptophan hydroxylase 1 expression. (Q54476060) (← links)
- A study of pipeline drugs in neuroendocrine tumors (Q84070923) (← links)
- Immersion Bioprinting of Tumor Organoids in Multi-Well Plates for Increasing Chemotherapy Screening Throughput (Q89834541) (← links)
- Alternate Endpoints for Phase II Trials in Advanced Neuroendocrine Tumors (Q90721580) (← links)